BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Welcome to Wessex Cancer Alliance - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://wessexcanceralliance.nhs.uk
X-WR-CALDESC:Events for Welcome to Wessex Cancer Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260210T133000
DTEND;TZID=Europe/London:20260210T163000
DTSTAMP:20260503T031410
CREATED:20251014T080506Z
LAST-MODIFIED:20251014T080506Z
UID:10000053-1770730200-1770741000@wessexcanceralliance.nhs.uk
SUMMARY:Targeted Treatments and Immunotherapy for Upper GI Cancers
DESCRIPTION:Date and Time: Tuesday 10th February 2026\, 13:30-16:30 \nCost: £90 \nFormat: Online \nDescription: In this half-day course\, Dr Elaine Vickers provides an overview of the targeted therapies and immunotherapies given to some people with oesophageal\, stomach\, pancreatic or liver cancer\, or cancers of the biliary system. \nElaine first looks briefly at the gene mutations and faulty processes and pathways that give rise to upper GI cancers and the factors that increase a person’s risk of these diseases. \nShe then turns her attention to the targeted treatments and immunotherapies that are relevant to oesophageal\, gastroesophageal junction\, stomach\, biliary\, liver\, and pancreatic cancer. \nCheckpoint inhibitor therapy is now used widely\, but it isn’t useful against every form of cancer. Elaine looks at why this is the case and why it is largely ineffective against pancreatic cancer. \nElaine will also describe various treatments that target mutated proteins found in cancer cells\, such as HER2\, FGFR\, and IDH1\, and the progress made to date in targeting Claudin 18.2. \nLastly\, Elaine will explain why pancreatic cancer is so difficult to treat and describe two promising strategies: personalised vaccines and Ras protein inhibitors. \nAudience: This course is ideal for research nurses\, clinical nurse specialists\, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with upper GI cancers. \nLink to Register: Targeted treatments and immunotherapy for Upper GI Cancers – Newcastle Hospitals Clinical Skills Academy
URL:https://wessexcanceralliance.nhs.uk/academy-event/targeted-treatments-and-immunotherapy-for-upper-gi-cancers/
ATTACH;FMTTYPE=image/jpeg:https://wessexcanceralliance.nhs.uk/wp-content/uploads/2025/06/Genomics.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260113T133000
DTEND;TZID=Europe/London:20260113T163000
DTSTAMP:20260503T031410
CREATED:20251014T080108Z
LAST-MODIFIED:20251014T080108Z
UID:10000052-1768311000-1768321800@wessexcanceralliance.nhs.uk
SUMMARY:Targeted Treatments and Immunotherapy for Bowel Cancer
DESCRIPTION:Date and Time: Tuesday 13th January 2026\, 13:30-16:30 \nCost: £90 \nFormat: Online \nDescription: Delivered over one afternoon session\, Dr Elaine Vickers provides an up-to-date overview of modern systemic treatment approaches given to people with bowel cancer including treatment combinations and new approaches currently being investigated in clinical trials. \nElaine first of all looks at the gene mutations and faulty processes and pathways that give rise to bowel cancer\, explaining the relationship between mismatch repair deficiency (dMMR) and microsatellite instability (MSI). \nShe then turns her attention to antibodies that target the EGF receptor (EGFR) and also summarises why they’re only effective for some people and looks at various reasons for resistance. \nCheckpoint inhibitor therapy has recently given highly promising results in trials\, but only if the tumour is dMMR/MSI. Elaine will describe why this is\, and explore whether immunotherapy might still hold promise for people whose cancers don’t display this characteristic. \nLastly\, Elaine will look at other targeted therapies and immunotherapies that have shown recent promise in trials. These include drugs that target B-Raf\, HER2 and Ras proteins. \nAudience: This half day course is ideal for research nurses\, clinical nurse specialists\, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with bowel cancer\, and to junior doctors. \nLink to Register: Targeted treatments and immunotherapy for Bowel Cancer – Newcastle Hospitals Clinical Skills Academy
URL:https://wessexcanceralliance.nhs.uk/academy-event/targeted-treatments-and-immunotherapy-for-bowel-cancer/
ATTACH;FMTTYPE=image/jpeg:https://wessexcanceralliance.nhs.uk/wp-content/uploads/2025/06/Genomics.jpg
END:VEVENT
END:VCALENDAR